The aim of this course is to provide cardiovascular physicians with current insights in ACE2 and the use of RAASi in the management of patients with COVID-19. Member registration (free) is needed to enroll in this course.

Watch a webinar on COVID-19, ACE2 and RAAS inhibition, including presentations on a scientific perspective and a clinical perspective, and in the end a discussion by 3 experts.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

This commentary article describes the function of ACE2, the receptor responsible for SARS-CoV-2 entry, and describes why continued use of RAS blockers during the COVID-19 pandemic is recommended.